NCT06222437

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Name: Clinical Trial NCT06222437
Creator: Methodist Health System
Keywords: Polycystic Ovary Syndrome, Semaglutide, Phase 1, drug, clinical trial, United States of America

Methodist Health System·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Polycystic Ovary Syndrome
Drug/Device/Intervention: Semaglutide
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Methodist Health System
Location: Dallas, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Jan 01, 2025
End date: Jan 01, 2026
Enrollment: 85 participants

Primary outcome

Number of appropriate weekly dose,Number of days on therapy

Summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

ICD-10 classifications

Polycystic ovarian syndromeOvarian dysfunction, unspecifiedOvarian dysfunctionOther ovarian dysfunctionNeoplasm of uncertain or unknown behaviour: Ovary

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06222437
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06222437 through Pure Global AI's free database. This Phase 1 trial is sponsored by Methodist Health System and is currently Not yet recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 85 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.